Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories

Drug Profile

Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories

Alternative Names: Allo iPS cell-derived retinal pigment epithelium; Cell therapies for ophthalmic diseases - Shin Nippon Biomedical Laboratories (SNBL)/RIKEN; Induced pluripotent stem (iPS) cells for eye disorders - Shin Nippon Biomedical Laboratories; iPS cell-derived RPE cell transplantation for Age-related macular degeneration - Healios/Shin Nippon Biomedical Laboratories; iPSC-derived RPE sheet - RIKEN/Healios; Retinal pigment epithelial (RPE) cells for AMD - Healios/RIKEN

Latest Information Update: 16 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RIKEN
  • Developer Healios; RIKEN; Shin Nippon Biomedical Laboratories
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration
  • No development reported Eye disorders

Most Recent Events

  • 31 Jan 2023 Preclinical development is still ongoing for Age-related macular degeneration in Japan (Intraocular)
  • 31 Jan 2023 Sumitomo Pharma plans a clinical trial for Age-related macular degeneration in Japan (Intraocular) in 2022
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Intraocular, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top